Background
Background The efficacy and safety of
The efficacy and safety of long-acting injectable risperidone have long-acting injectable risperidone have not been compared with those of an oral not been compared with those of an oral atypical antipsychotic. atypical antipsychotic.
Aims Aims To compare long-acting
To compare long-acting risperidone and oral olanzapine in risperidone and oral olanzapine in 377 patients with DSM^IV schizophrenia 377 patients with DSM^IV schizophrenia or schizoaffective disorder. or schizoaffective disorder.
Method Method Patients were randomised to
Patients were randomised to receive long-acting risperidone (25 mg receive long-acting risperidone (25 mg or 50 mg every14 days) or olanzapine or 50 mg every14 days) or olanzapine (5^20 mg/day). (5^20 mg/day).
Results
Results In the13-week phase, longIn the13-week phase, longacting risperidone was at least as acting risperidone was at least as effective as (not inferior to) oral effective as (not inferior to) oral olanzapine.In the12-month phase, olanzapine.In the12-month phase, significant improvements in the Positive significant improvements in the Positive and Negative Syndrome Scale (PANSS) and Negative Syndrome Scale (PANSS) total and factor scores from baseline to total and factor scores from baseline to month12 and end-point were seen in both month12 and end-point were seen in both groups of patients.Few patients groups of patients.Few patients discontinued treatment because of an discontinued treatment because of an adverse event. adverse event.
The efficacy and safety of long-acting inThe efficacy and safety of long-acting injectable risperidone have been evaluated jectable risperidone have been evaluated in several trials of patients with schizoin several trials of patients with schizophrenia or schizoaffective disorder, includphrenia or schizoaffective disorder, including a 12-week, double-blind, placeboing a 12-week, double-blind, placebocontrolled study ( controlled study (n n¼554; Kane 554; Kane et al et al, , 2003) 2003) . The , 2003) . The effectiveness of long-acting risperidone has effectiveness of long-acting risperidone has also been demonstrated in patients also been demonstrated in patients switched from typical and atypical oral switched from typical and atypical oral antipsychotic medication (Lindenmayer antipsychotic medication (Lindenmayer et et al al, 2004; Chue , 2004; Chue et al et al, 2005) and from con-, 2005) and from conventional depot antipsychotics (Turner ventional depot antipsychotics (Turner et et al al, 2004) .
, 2004). In the 12-week double-blind In the 12-week double-blind study by Chue study by Chue et al et al (2005) , long-acting ris-(2005), long-acting risperidone was compared with oral risperiperidone was compared with oral risperidone in patients with schizophrenia. Both done in patients with schizophrenia. Both treatments were efficacious and well tolertreatments were efficacious and well tolerated. According to a non-inferiority analysis, ated. According to a non-inferiority analysis, the two treatments showed comparable effithe two treatments showed comparable efficacy in Positive and Negative Syndrome cacy in Positive and Negative Syndrome Scale (PANSS; Kay Scale (PANSS; Kay et al et al, 1987) total scores , 1987) total scores over the short term. Long-acting risperiover the short term. Long-acting risperidone, however, has not been compared done, however, has not been compared with an oral formulation of another atypical with an oral formulation of another atypical antipsychotic such as olanzapine. In this 53-antipsychotic such as olanzapine. In this 53-week, open-label, randomised controlled week, open-label, randomised controlled international study (registered with the international study (registered with the US National Institutes of Health at US National Institutes of Health at http://clinicaltrials.gov as NCT00236457) http://clinicaltrials.gov as NCT00236457) we compared long-acting risperidone we compared long-acting risperidone with with olanzapine tablets in patients with schizoolanzapine tablets in patients with schizophrenia or schizoaffective disorder. phrenia or schizoaffective disorder.
The objectives of the study were, first, The objectives of the study were, first, to demonstrate that in the short term to demonstrate that in the short term long-acting injectable risperidone was at long-acting injectable risperidone was at least as effective as (not inferior to) oral least as effective as (not inferior to) oral olanzapine in patients with schizophrenia olanzapine in patients with schizophrenia or schizoaffective disorder. Non-inferiority or schizoaffective disorder. Non-inferiority would be demonstrated if, at the end of would be demonstrated if, at the end of the initial 13-week treatment period, the the initial 13-week treatment period, the upper limit of the confidence interval for upper limit of the confidence interval for the difference in mean change from baseline the difference in mean change from baseline in PANSS total scores was not more than in PANSS total scores was not more than 8 points in favour of oral olanzapine. The 8 points in favour of oral olanzapine. The second objective was to examine the longsecond objective was to examine the longterm efficacy and safety of long-acting term efficacy and safety of long-acting risperidone and oral olanzapine in these risperidone and oral olanzapine in these patients. patients.
METHOD METHOD
The study protocol and amendments were The study protocol and amendments were reviewed by independent ethics committees reviewed by independent ethics committees or institutional review boards. The study or institutional review boards. The study was conducted in accordance with the was conducted in accordance with the recommendations guiding physicians in recommendations guiding physicians in biomedical research involving humans conbiomedical research involving humans contained in the 1989 version of the Declaratained in the 1989 version of the Declaration of Helsinki and according to the tion of Helsinki and according 
Participants Participants
Patients with schizophrenia or schizoaffecPatients with schizophrenia or schizoaffective disorder were recruited at 48 centres tive disorder were recruited at 48 centres (in Australia, Belgium, France, Germany, (in Australia, Belgium, France, Germany, Greece, Luxembourg, Poland, Russia, Greece, Luxembourg, Poland, Russia, Spain, The Netherlands and the UK). IncluSpain, The Netherlands and the UK). Inclusion criteria included a diagnosis of schizosion criteria included a diagnosis of schizophrenia or schizoaffective disorder (DSMphrenia or schizoaffective disorder (DSM-IV; American Psychiatric Association, IV; American Psychiatric Association, 1994); PANSS total score 50 or over at 1994); PANSS total score 50 or over at randomisation; age at least 18 years; body randomisation; age at least 18 years; body mass index (BMI) not exceeding 40 mg/ mass index (BMI) not exceeding 40 mg/ kg kg 2 2 ; and the requirement that within the ; and the requirement that within the previous 2 months the patient had been previous 2 months the patient had been hospitalised or required medical intervenhospitalised or required medical intervention for an acute exacerbation of psychosis tion for an acute exacerbation of psychosis and had experienced an additional acute and had experienced an additional acute exacerbation during the previous 2 years. exacerbation during the previous 2 years. Exclusion criteria were prior treatment Exclusion criteria were prior treatment with clozapine or with a depot antiwith clozapine or with a depot antipsychotic within one treatment cycle before psychotic within one treatment cycle before screening, and resistance or sensitivity to screening, and resistance or sensitivity to risperidone or olanzapine. Also excluded risperidone or olanzapine. Also excluded were women who were pregnant or were women who were pregnant or breast-feeding or, if of child-bearing age, breast-feeding or, if of child-bearing age, not using adequate contraception. not using adequate contraception.
Protocol deviations that warranted exProtocol deviations that warranted exclusion from the primary efficacy analysis clusion from the primary efficacy analysis were: were:
(a) (a) patients who discontinued before week patients who discontinued before week 8 of treatment (to meet International 8 of treatment (to meet International Conference on Harmonisation guideConference on Harmonisation guidelines); lines); (b) (b) patients who received additional antipatients who received additional antipsychotic treatment (other than oral psychotic treatment (other than oral risperidone for patients in the risperirisperidone for patients in the risperidone arm or olanzapine in the olanzadone arm or olanzapine in the olanzapine arm) between the end of run-in pine arm) between the end of run-in and the end of the first 13-week period; and the end of the first 13-week period;
(c) (c) patients who started treatment with a patients who started treatment with a depot antipsychotic within one treatdepot antipsychotic within one treatment cycle before the randomisation ment cycle before the randomisation visit or who started another depot treatvisit or who started another depot treatment during the initial 13-week period. ment during the initial 13-week period.
Randomisation Randomisation
The patients were randomised to receive The patients were randomised to receive long-acting risperidone or olanzapine, with long-acting risperidone or olanzapine, with stratification factors of psychopathology stratification factors of psychopathology (PANSS total scores), number of previous (PANSS total scores), number of previous psychiatric hospitalisations, BMI and inpsychiatric hospitalisations, BMI and inpatient or out-patient status, using a central patient or out-patient status, using a central dynamic randomisation procedure. Randynamic randomisation procedure. Randomisation was based on a minimisation domisation was based on a minimisation algorithm that used a probability of assignalgorithm that used a probability of assignment other than 0.5 to maintain balance of ment other than 0.5 to maintain balance of treatment groups within levels of each treatment groups within levels of each stratification factor. Constraints on imbalstratification factor. Constraints on imbalance were defined within each level of each ance were defined within each level of each factor; violation of a constraint resulted in factor; violation of a constraint resulted in adjustment to the treatment assignment adjustment to the treatment assignment probabilities. Randomisation numbers were probabilities. Randomisation numbers were allocated by an interactive voice response allocated by an interactive voice response system (IVRS). When a participant was system (IVRS). When a participant was ready to be randomised, the investigator ready to be randomised, the investigator called the IVRS by telephone and entered called the IVRS by telephone and entered the person's stratification information. the person's stratification information. Based on the minimisation algorithm, the Based on the minimisation algorithm, the IVRS returned the randomisation number IVRS returned the randomisation number of the appropriate box of study medication of the appropriate box of study medication at the site. at the site.
Dosing and delivery of long-acting Dosing and delivery of long-acting risperidone risperidone
According to the original study protocol, According to the original study protocol, patients in the long-acting risperidone patients in the long-acting risperidone group received 25, 50 or 75 mg of longgroup received 25, 50 or 75 mg of longacting risperidone. After study initiation, acting risperidone. After study initiation, the original clinical trial programme rethe original clinical trial programme revealed that the 75 mg dose provided no vealed that the 75 mg dose provided no greater benefit than the lower doses and greater benefit than the lower doses and the protocol was amended to restrict doses the protocol was amended to restrict doses to 25 or 50 mg of long-acting risperidone. to 25 or 50 mg of long-acting risperidone. The 64 patients who had already received The 64 patients who had already received 75 mg of long-acting risperidone completed 75 mg of long-acting risperidone completed the end-point visit and were then withthe end-point visit and were then withdrawn from this study and invited to enrol drawn from this study and invited to enrol in an open-label extension study. Thus, in an open-label extension study. Thus, patients receiving 25 or 50 mg of longpatients receiving 25 or 50 mg of longacting risperidone were the focus of the acting risperidone were the focus of the analyses reported here. analyses reported here. During week 1 of the study previous During week 1 of the study previous antipsychotic treatments were discontinued antipsychotic treatments were discontinued and replaced with oral risperidone. The and replaced with oral risperidone. The dose of oral risperidone was adjusted to 2, dose of oral risperidone was adjusted to 2, 4 or 6 mg according to each patient's 4 or 6 mg according to each patient's clinical response. The initial dose of longclinical response. The initial dose of longacting risperidone was determined by a acting risperidone was determined by a protocol-specified conversion scheme: protocol-specified conversion scheme: patients who had received 2-4 mg of oral patients who had received 2-4 mg of oral risperidone during week 1 received 25 mg risperidone during week 1 received 25 mg per 14 days of long-acting risperidone and per 14 days of long-acting risperidone and patients who had received 6 mg of oral rispatients who had received 6 mg of oral risperidone during week 1 received 50 mg per peridone during week 1 received 50 mg per 14 days of long-acting risperidone. The 14 days of long-acting risperidone. The dosage of long-acting risperidone could be dosage of long-acting risperidone could be adjusted during the trial according to each adjusted during the trial according to each patient's clinical response. Before the protopatient's clinical response. Before the protocol was amended and doses were restricted col was amended and doses were restricted to 25 and 50 mg of long-acting risperidone, to 25 and 50 mg of long-acting risperidone, patients who had received 6 mg of oral patients who had received 6 mg of oral risperidone during week 1 received 75 mg risperidone during week 1 received 75 mg of long-acting risperidone. of long-acting risperidone.
Oral risperidone at the week 1 dosage Oral risperidone at the week 1 dosage was continued for 3 weeks after the first inwas continued for 3 weeks after the first injection of long-acting risperidone. Oral risjection of long-acting risperidone. Oral risperidone supplementation was given when peridone supplementation was given when necessary after the initial 3 weeks. necessary after the initial 3 weeks.
Dosages of oral olanzapine Dosages of oral olanzapine
During week 1 previous medications were During week 1 previous medications were discontinued and oral olanzapine was discontinued and oral olanzapine was introduced and adjusted to the patients' introduced and adjusted to the patients' optimal dosage of 5-20 mg/day at daily optimal dosage of 5-20 mg/day at daily increments of 5 mg. During weeks 2-53 increments of 5 mg. During weeks 2-53 the patients received flexible dosages of the patients received flexible dosages of 5-20 mg/day of olanzapine. 5-20 mg/day of olanzapine.
Assessments of efficacy and safety Assessments of efficacy and safety
The primary measure of efficacy was the The primary measure of efficacy was the change in total score on the PANSS (Strucchange in total score on the PANSS (Structured Clinical Interview) from baseline to tured Clinical Interview) from baseline to end-point (last observation carried forend-point (last observation carried forward, LOCF) in the initial 13-week period ward, LOCF) in the initial 13-week period (short-term outcome). The secondary mea-(short-term outcome). The secondary measures (long-term outcomes) were the sures (long-term outcomes) were the changes in PANSS total scores from basechanges in PANSS total scores from baseline to month 12 and end-point; changes line to month 12 and end-point; changes in PANSS factor scores (positive symptoms, in PANSS factor scores (positive symptoms, negative symptoms, disorganised thoughts, negative symptoms, disorganised thoughts, uncontrolled hostility/excitement and anxiuncontrolled hostility/excitement and anxiety/depression; Marder ety/depression; Marder et al et al, 1997); and , 1997); and changes in scores on the Clinical Global Imchanges in scores on the Clinical Global Impression -Severity (CGI-S; Guy, 1976) pression -Severity (CGI-S; Guy, 1976) scale. Quality of life was evaluated by scale. Quality of life was evaluated by means of the Wisconsin Quality of Life Inmeans of the Wisconsin Quality of Life Index (Becker dex (Becker et al et al, 1993) . The Wisconsin test , 1993). The Wisconsin test was designed for patients with severe menwas designed for patients with severe mental illness and comprises nine dimensions: tal illness and comprises nine dimensions: life satisfaction, occupational activities, life satisfaction, occupational activities, psychological well-being, physical health, psychological well-being, physical health, social relations, economics, activities of social relations, economics, activities of daily living, symptoms and the patient's daily living, symptoms and the patient's own goals. own goals.
Clinical improvement was defined as a Clinical improvement was defined as a 20% or greater reduction in PANSS total 20% or greater reduction in PANSS total scores. Maintenance of effect was assessed scores. Maintenance of effect was assessed by determining the time to significant by determining the time to significant deterioration in the psychotic condition, deterioration in the psychotic condition, defined as hospitalisation for symptom defined as hospitalisation for symptom exacerbation; the need for an increased exacerbation; the need for an increased level of care and an increase in CGI-S level of care and an increase in CGI-S scores of 2 points or more over a 2-week scores of 2 points or more over a 2-week period; or self-injury, suicidal or homicidal period; or self-injury, suicidal or homicidal ideation or violent behaviour. Significant ideation or violent behaviour. Significant psychotic deterioration was assessed in the psychotic deterioration was assessed in the total group and in patients who were rated total group and in patients who were rated as stabilised after 13 weeks of treatment. A as stabilised after 13 weeks of treatment. A patient was considered stabilised if he or patient was considered stabilised if he or she had been on the same dosage for 4 she had been on the same dosage for 4 weeks or more, the PANSS total score at weeks or more, the PANSS total score at week 13 did not exceed 70 and the CGI-S week 13 did not exceed 70 and the CGI-S score at weeks 9 and 13 was 3 or below score at weeks 9 and 13 was 3 or below and did not increase between weeks 9 and 13. and did not increase between weeks 9 and 13.
Assessments were completed at baseline Assessments were completed at baseline (randomisation), weeks 5, 9, 13, 25, 37 and (randomisation), weeks 5, 9, 13, 25, 37 and 53 and at end-point (last observation car-53 and at end-point (last observation carried forward, LOCF). The CGI-S was also ried forward, LOCF). The CGI-S was also completed at weeks 1 and 3 and psychotic completed at weeks 1 and 3 and psychotic deterioration was evaluated at week 3. Addeterioration was evaluated at week 3. Adverse events were recorded at each visit. Severse events were recorded at each visit. Severity of movement disorders was assessed verity of movement disorders was assessed by means of the Simpson-Angus Rating by means of the Simpson-Angus Rating Scale (SARS; Simpson & Angus, 1970) at Scale (SARS; Simpson & Angus, 1970) at baseline, at weeks 13, 25, 37 and 53 and baseline, at weeks 13, 25, 37 and 53 and at end-point. at end-point.
Statistical analysis Statistical analysis
Differences in changes in PANSS total Differences in changes in PANSS total scores from baseline to end-point (LOCF) scores from baseline to end-point (LOCF) in the 13-week study between the two treatin the 13-week study between the two treatment groups were evaluated by an analysis ment groups were evaluated by an analysis of covariance (ANCOVA) model. Factors of covariance (ANCOVA) model. Factors included in the model were baseline PANSS included in the model were baseline PANSS score as covariate, randomisation group, score as covariate, randomisation group, the stratification variables (excluding the the stratification variables (excluding the PANSS factor since it was included as cov-PANSS factor since it was included as covariate) and investigator nested in country. ariate) and investigator nested in country. Because some investigators had only a few Because some investigators had only a few patients, pooling of some investigators patients, pooling of some investigators and countries was required for the fixed-efand countries was required for the fixed-effects ANCOVA model. To avoid pooling, fects ANCOVA model. To avoid pooling, an additional ANCOVA model was peran additional ANCOVA model was performed (for 13 weeks, month 12 visit and formed (for 13 weeks, month 12 visit and end-point) in which country and investigaend-point) in which country and investigator were treated as random effects. The tor were treated as random effects. The number and proportion of patients who number and proportion of patients who achieved clinical improvement were tabuachieved clinical improvement were tabulated at each assessment point and at endlated at each assessment point and at endpoint. The 95% CI of the odds ratios of point. The 95% CI of the odds ratios of the two treatment groups was obtained at the two treatment groups was obtained at month 12 and at end-point. A logistic modmonth 12 and at end-point. A logistic model (with logit link function and binomial el (with logit link function and binomial error structure) was applied with the error structure) was applied with the stratification variables as fixed effects and stratification variables as fixed effects and investigator as random effect. investigator as random effect.
LONG -AC T ING R I S P E R ID ONE LON G -AC T IN G R I S P E R I D ONE V. V. OR A L OL ANZ A P INE OR A L OL ANZ A P INE
The number and proportion of partiThe number and proportion of participants who experienced a significant detecipants who experienced a significant deterioration were tabulated at each assessment rioration were tabulated at each assessment point and at end-point. A Cox proportional point and at end-point. A Cox proportional hazards model (controlling for the four hazards model (controlling for the four stratification variables and stratified by stratification variables and stratified by country) was used to obtain the 95% CI country) was used to obtain the 95% CI of the ratio of the hazards in both treatment of the ratio of the hazards in both treatment groups. groups.
RESULTS RESULTS
Of the 618 patients who were randomised Of the 618 patients who were randomised and treated (318 to long-acting risperidone and treated (318 to long-acting risperidone and 300 to olanzapine), 64 were excluded and 300 to olanzapine), 64 were excluded from the short-term (weeks 1-13) analysis from the short-term (weeks 1-13) analysis of efficacy because they received injections of efficacy because they received injections of 75 mg of long-acting risperidone; 66 of 75 mg of long-acting risperidone; 66 (38 risperidone and 28 olanzapine patients) (38 risperidone and 28 olanzapine patients) were excluded because of major protocol were excluded because of major protocol deviations and 110 (52 risperidone and 58 deviations and 110 (52 risperidone and 58 olanzapine patients) were excluded because olanzapine patients) were excluded because of non-adherence to Good Clinical Practice of non-adherence to Good Clinical Practice standards at one study site. The principal standards at one study site. The principal protocol deviations were use of unapproved protocol deviations were use of unapproved concomitant medications and inadequate concomitant medications and inadequate duration of treatment. Thus the per-protocol duration of treatment. Thus the per-protocol short-term sample included 164 patients in short-term sample included 164 patients in the long-acting risperidone group and 214 the long-acting risperidone group and 214 in the olanzapine group (Fig. 1) . For the in the olanzapine group (Fig. 1) . For the analysis of long-term analysis of long-term treatment (months 1-treatment (months 1-12) a further 2 patients 12) a further 2 patients were excluded bewere excluded because they received 75 mg of long-acting cause they received 75 mg of long-acting risperidone and 14 patients (7 risperidone risperidone and 14 patients (7 risperidone and 7 olanzapine) were excluded because and 7 olanzapine) were excluded because of major protocol deviations. Thus the of major protocol deviations. Thus the per-protocol long-term sample for the evaper-protocol long-term sample for the evaluation of efficacy included 155 patients luation of efficacy included 155 patients in the long-acting risperidone group and in the long-acting risperidone group and 207 in the olanzapine group (Fig. 1) . Safety 207 in the olanzapine group (Fig. 1) . Safety was evaluated in all randomised particiwas evaluated in all randomised participants who received at least one dose of pants who received at least one dose of study medication and did not receive a study medication and did not receive a 75 mg injection during the entire trial: 247 75 mg injection during the entire trial: 247 in the long-acting risperidone group and in the long-acting risperidone group and 300 in the olanzapine group. 300 in the olanzapine group.
Patient characteristics Patient characteristics and disposition and disposition
Background characteristics of the two Background characteristics of the two patient groups were similar (Table 1) . patient groups were similar (Table 1) . Of Of the 547 patients who were randomised, rethe 547 patients who were randomised, received at least one dose of study medication ceived at least one dose of study medication and did not receive a 75 mg injection during and did not receive a 75 mg injection during the entire trial, 347 (63%) completed the the entire trial, 347 (63%) completed the 12-month trial. These included 160 (65%) 12-month trial. These included 160 (65%) of the long-acting risperidone group and of the long-acting risperidone group and 187 (62%) of the oral olanzapine group 187 (62%) of the oral olanzapine group (Fig. 1, Table 2 ). (Fig. 1, Table 2 ). 13 3 13 3 AUTHOR'S PROOF AUTHOR'S PROOF 
Concomitant medications Concomitant medications
Concomitant medications were received by Concomitant medications were received by 85% of patients in the long-acting risperidone 85% of patients in the long-acting risperidone group and 80% of patients in the olanzagroup and 80% of patients in the olanzapine group. These included sedatives or pine group. These included sedatives or hypnotics, taken by 65 and 53% respechypnotics, taken by 65 and 53% respectively; antidepressants, taken by 43 and tively; antidepressants, taken by 43 and 34%; antiparkinsonian drugs, taken by 37 34%; antiparkinsonian drugs, taken by 37 and 18%; anticonvulsants, taken by 21 and 18%; anticonvulsants, taken by 21 and 19%; and muscle relaxants, by 11 and 19%; and muscle relaxants, by 11 and 10% respectively. and 10% respectively.
Medication adherence Medication adherence
Medication adherence was high. In the risMedication adherence was high. In the risperidone group the mean injection interval peridone group the mean injection interval was 14.2 days (range 13-16) and in the was 14.2 days (range 13-16) and in the olanzapine group the mean time off drug olanzapine group the mean time off drug per patient was 0.7 days (s.d. per patient was 0.7 days (s.d.¼3.7, range 3.7, range 0-52). 0-52).
Efficacy Efficacy
Short-term outcome (weeks 1^13) Short-term outcome (weeks 1^13)
The upper limit of the PANSS 95% CI (score The upper limit of the PANSS 95% CI (score of 3.0) was well below the non-inferiority of 3.0) was well below the non-inferiority margin (score of 8), demonstrating the primargin (score of 8), demonstrating the primary end-point that long-acting risperidone mary end-point that long-acting risperidone was at least as effective as olanzapine was at least as effective as olanzapine (Table 3) . (Table 3) .
Long-term outcomes (months 1^12) Long-term outcomes (months 1^12)
Significant improvements in PANSS total Significant improvements in PANSS total and factor scores from baseline to month and factor scores from baseline to month 12 and end-point were seen in both groups 12 and end-point were seen in both groups of patients (Table 3 , Fig. 2) . Among the of patients (Table 3 , Fig. 2 ). Among the patients who completed the long-term trial, patients who completed the long-term trial, significantly greater improvement on one significantly greater improvement on one PANSS factor score (disorganised thoughts, PANSS factor score (disorganised thoughts, P P5 50.05) was seen in patients receiving 0.05) was seen in patients receiving long-acting risperidone than in those long-acting risperidone than in those receiving oral olanzapine (Table 3) . At receiving oral olanzapine (Table 3) . At end-point, end-point, significantly greater improvement significantly greater improvement in anxiety/depression was seen in the olanzain anxiety/depression was seen in the olanzapine group. pine group.
Clinical improvement (20% minimum Clinical improvement (20% minimum reduction in PANSS total scores) was reduction in PANSS total scores) was achieved by significantly more patients achieved by significantly more patients receiving long-acting risperidone than those receiving long-acting risperidone than those receiving oral olanzapine at month 12 (91 receiving oral olanzapine at month 12 (91 v. v. 79%; 79%; P P5 50.001), based on a logistic 0.001), based on a logistic 13 4 13 4 AUTHOR'S PROOF AUTHOR'S PROOF 
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regression model controlling for in-patient/ regression model controlling for in-patient/ out-patient status, BMI, number of preout-patient status, BMI, number of previous hospitalisations and investigator. At vious hospitalisations and investigator. At end-point, 79% of patients in the longend-point, 79% of patients in the longacting risperidone group and 73% in the acting risperidone group and 73% in the olanzapine group achieved clinical imolanzapine group achieved clinical improvement ( provement (P P¼0.057; Fig. 3 ). Similar re-0.057; Fig. 3 ). Similar reductions in the overall severity of illness ductions in the overall severity of illness (CGI-S score) were seen in the long-acting (CGI-S score) were seen in the long-acting risperidone and olanzapine groups: mean risperidone and olanzapine groups: mean CGI-S scores at baseline were 3.1 CGI-S scores at baseline were 3. 2) respectively. The proportions of patients spectively. The proportions of patients who were rated as 'not ill' or 'mildly ill' inwho were rated as 'not ill' or 'mildly ill' increased respectively from 19 and 17% at creased respectively from 19 and 17% at baseline to 82 and 76% at month 12 and baseline to 82 and 76% at month 12 and 66 and 67% at end-point. Mean scores on 66 and 67% at end-point. Mean scores on the patient version of the Wisconsin Qualthe patient version of the Wisconsin Quality of Life Index were similar in the two ity of Life Index were similar in the two treatment groups at baseline: 0. . Patients' quality of life improved from baseline to quality of life improved from baseline to end-point on all sub-scale ratings. Clinically end-point on all sub-scale ratings. Clinically meaningful improvements (score changes meaningful improvements (score changes 4 40.5 points) were seen in three domains 0.5 points) were seen in three domains in both treatment groups: occupational in both treatment groups: occupational activities, psychological well-being and activities, psychological well-being and symptoms/outlook. symptoms/outlook.
Maintenance of effect Maintenance of effect
The proportion of patients with significant The proportion of patients with significant deterioration in psychotic symptoms was deterioration in psychotic symptoms was 0.6% in the long-acting risperidone group 0.6% in the long-acting risperidone group and 2.0% in the olanzapine group at week and 2.0% in the olanzapine group at week 3; these respective proportions rose to 3% 3; these respective proportions rose to 3% and 2% at week 13 and at month 12 and and 2% at week 13 and at month 12 and to 10% and 9% at end-point. The time to to 10% and 9% at end-point. The time to first deterioration was comparable in the first deterioration was comparable in the 13 5 13 5 AUTHOR'S PROOF AUTHOR'S PROOF Table 3  Table 3 Positive and Negative Syndrome Scale total and factor scores in patients receiving long-acting risperidone or olanzapine Positive and Negative Syndrome Scale total and factor scores in patients receiving long-acting risperidone or olanzapine 0.6 (0.1 to 1.2)* 0.6 (0.1 to 1.2)* LSM, least squares mean; PANSS, Positive and Negative Syndrome Scale. LSM, least squares mean; PANSS, Positive and Negative Syndrome Scale. 1. Least squares means. Short-term analysis: analysis of covariance with factors randomisation group, body mass index, number of previous hospitalisations, patient status and 1. Least squares means. Short-term analysis: analysis of covariance with factors randomisation group, body mass index, number of previous hospitalisations, patient status and country country6 6investigator and baseline score as covariate (type III sum of squares, SS). Long-term analysis: mixed-effects model with fixed effects of randomisation group, body mass ininvestigator and baseline score as covariate (type III sum of squares, SS). Long-term analysis: mixed-effects model with fixed effects of randomisation group, body mass index, number of previous hospitalisations, patient status, random effects for country and investigator, and baseline score as covariate (type III SS). dex, number of previous hospitalisations, patient status, random effects for country and investigator, and baseline score as covariate (type III SS). 2. Baseline PANSS scores were not available for one olanzapine-group patient in the short-term analysis and for one patient in each group in the long-term analysis. 2. Baseline PANSS scores were not available for one olanzapine-group patient in the short-term analysis and for one patient in each group in the long-term analysis. 3. All changes in PANSS total and factor scores from baseline to month 12 and end-point were significant ( 3. All changes in PANSS total and factor scores from baseline to month 12 and end-point were significant (P P5 50.0001; paired 0.0001; paired t t-test). -test). * *P P5 50.05. 0.05. two groups (hazard ratio 1.38, 95% CI two groups (hazard ratio 1.38, 95% CI 0.82-2.33). Among the 179 0.82-2.33). Among the 179 patients who patients who were stabilised at week 13, significant detewere stabilised at week 13, significant deterioration was noted in 3% of both the longrioration was noted in 3% of both the longacting risperidone group and the olanzaacting risperidone group and the olanzapine group at month 12, and in 5% and pine group at month 12, and in 5% and 6% respectively at end-point. The time to 6% respectively at end-point. The time to first deterioration was comparable in the first deterioration was comparable in the two groups (hazard ratio 1.37, 95% CI two groups (hazard ratio 1.37, 95% CI 0.47-3.99). 0.47-3.99).
Safety Safety

Adverse events Adverse events
Treatment-emergent adverse events reTreatment-emergent adverse events reported by 5% or more of patients in either ported by 5% or more of patients in either group are listed in Table 4 . Adverse events group are listed in Table 4 . Adverse events resulted in treatment discontinuation for 7 resulted in treatment discontinuation for 7 patients in the long-acting risperidone patients in the long-acting risperidone group (3%) and 11 patients in the olanzagroup (3%) and 11 patients in the olanzapine group (4%). Serious adverse events pine group (4%). Serious adverse events were reported by 23% of the patients in were reported by 23% of the patients in the long-acting risperidone group and the long-acting risperidone group and 21% of the olanzapine group (Table 4) . 21% of the olanzapine group (Table 4) .
Adverse events related to extrapyramiAdverse events related to extrapyramidal symptoms were reported by 25% of dal symptoms were reported by 25% of the long-acting risperidone group and the long-acting risperidone group and 15% of the olanzapine group ( 15% of the olanzapine group (P P5 50.05; 0.05; Table 5 ). Only one patient (in the long- Table 5 ). Only one patient (in the longacting risperidone group) discontinued acting risperidone group) discontinued treatment because of an extrapyramidal treatment because of an extrapyramidal adverse event (hyperkinesia). Severity of adverse event (hyperkinesia). Severity of extrapyramidal symptoms was mild in both extrapyramidal symptoms was mild in both treatment groups. Median scores on the treatment groups. Median scores on the SARS -scores range from 0 (no symptom) SARS -scores range from 0 (no symptom) to 4 (extreme) -were 0 at all time points to 4 (extreme) -were 0 at all time points in both treatment groups. At end-point, in both treatment groups. At end-point, SARS total scores ranged from 0 to 1.5 in SARS total scores ranged from 0 to 1.5 in the long-acting risperidone group and from the long-acting risperidone group and from 0 to 1.7 in the olanzapine group. New-0 to 1.7 in the olanzapine group. Newonset tardive dyskinesia was reported in onset tardive dyskinesia was reported in two patients in each treatment group. two patients in each treatment group.
Treatment-emergent sexual side-effects Treatment-emergent sexual side-effects were reported by 3% of the patients in each were reported by 3% of the patients in each treatment group. The most common of treatment group. The most common of these were non-puerperal lactation (in five these were non-puerperal lactation (in five patients in the long-acting risperidone patients in the long-acting risperidone group and two patients in the olanzapine group and two patients in the olanzapine group) and impotence (in two patients in group) and impotence (in two patients in each group). One patient in each group each group). One patient in each group discontinued because of a sexual side-effect. discontinued because of a sexual side-effect. Glucose-related adverse events were Glucose-related adverse events were reported in 2% of patients in both the reported in 2% of patients in both the long-acting risperidone and olanzapine long-acting risperidone and olanzapine groups. These included diabetes mellitus groups. These included diabetes mellitus in one patient in each group; hyperglyin one patient in each group; hyperglycaemia in four patients in each group; and caemia in four patients in each group; and hypoglycaemia in one patient in the hypoglycaemia in one patient in the olanzapine group. No clinically relevant olanzapine group. No clinically relevant change in mean laboratory test values was change in mean laboratory test values was seen in either treatment group. seen in either treatment group.
Deaths Deaths
Eight patients died during the study or soon Eight patients died during the study or soon after its termination, two in the long-acting after its termination, two in the long-acting risperidone group and six in the olanzapine risperidone group and six in the olanzapine group. Causes of death were accident ( group. Causes of death were accident (n n¼1) 1) and oesophageal cancer ( and oesophageal cancer (n n¼1) in the long-1) in the longacting risperidone group, and cardiac acting risperidone group, and cardiac insufficiency/circulatory insufficiency ( insufficiency/circulatory insufficiency (n n¼1), 1), status epilepticus/myocardial ischaemia, status epilepticus/myocardial ischaemia, ( (n n¼1) myocardial infarction ( 1) myocardial infarction (n n¼1), pneu-1), pneumonia ( monia (n n¼1), and suicide ( 1), and suicide (n n¼2) in the 2) in the olanzapine group. olanzapine group.
Body weight Body weight
Body weight increased by 1.7 kg in the Body weight increased by 1.7 kg in the long-acting risperidone group and by long-acting risperidone group and by 4.0 kg in the olanzapine group ( 4.0 kg in the olanzapine group (P P5 50.05; 0.05; Fig. 4 ). Body weight increases of 7% or Fig. 4) . Body weight increases of 7% or more were seen in 20% of the long-acting more were seen in 20% of the long-acting risperidone group and 36% of the olanzarisperidone group and 36% of the olanzapine group; decreases of 7% were seen in pine group; decreases of 7% were seen in 6% of patients in both groups. Body mass 6% of patients in both groups. Body mass index increased by 0.6 kg/m index increased by 0.6 kg/m 2 2 in the longin the longacting risperidone group and by 1.4 kg/m acting risperidone group and by 1.4 kg/m 2 2 in the olanzapine group ( in the olanzapine group (P P<0.05). Six <0.05). Six patients discontinued because of weight patients discontinued because of weight gain, one in the risperidone group and five gain, one in the risperidone group and five in the olanzapine group. in the olanzapine group.
Patients receiving 75 mg long-acting Patients receiving 75 mg long-acting risperidone risperidone
The PANSS total and factor scores and The PANSS total and factor scores and adverse events in patients receiving 75 mg adverse events in patients receiving 75 mg of long-acting risperidone are reported in of long-acting risperidone are reported in Tables 6 and 7 . In these patients, who had Tables 6 and 7 . In these patients, who had 13 6 13 6 AUTHOR'S PROOF AUTHOR'S PROOF Table 4  Table 4 Adverse events reported by at least 5% of Adverse events reported by at least 5% of patients and serious adverse events reported by at patients and serious adverse events reported by at least 2% of patients in either group least 2% of patients in either group 1. Adverse events reported by 1. Adverse events reported by 5 55% of patients (ris-5% of patients (risperidone group peridone group n n¼238, olanzapine group 238, olanzapine group n n¼294). 294). 2. Serious adverse events reported by 2. Serious adverse events reported by 5 52% of patients 2% of patients (risperidone group (risperidone group n n¼247, olanzapine group 247, olanzapine group n n¼300). 300). Table 5  Table 5 Adverse events related to extrapyramidal Adverse events related to extrapyramidal symptoms reported in the two patient groups symptoms reported in the two patient groups 
LONG -AC T ING R I S P E R ID ONE LON G -AC T IN G R I S P E R I D ONE V. V. OR A L OL ANZ A P INE OR A L OL ANZ A P INE
received 6 mg (the highest dose) of oral risreceived 6 mg (the highest dose) of oral risperidone during week 1, mean PANSS total peridone during week 1, mean PANSS total and factor scores at baseline were substanand factor scores at baseline were substantially higher than in patients receiving 25 tially higher than in patients receiving 25 or 50 mg of long-acting risperidone. More or 50 mg of long-acting risperidone. More adverse events were also reported in this adverse events were also reported in this group. group.
DISCUSSION DISCUSSION
Risperidone and olanzapine have been Risperidone and olanzapine have been shown to be effective and generally well shown to be effective and generally well tolerated both in short-term (Marder & tolerated both in short-term (Marder & Meibach, 1994; Tollefson Meibach, 1994; Tollefson et al et al, 1997) (2001) reported that the efficacy and safety of risperidone and olanzapine and safety of risperidone and olanzapine were generally similar in their double-blind, were generally similar in their double-blind, 8-week study. The only significant be-8-week study. The only significant between-group differences were the greater tween-group differences were the greater improvements in the risperidone-treated improvements in the risperidone-treated patients on two of the five PANSS factors patients on two of the five PANSS factors (positive symptoms and anxiety/depression) (positive symptoms and anxiety/depression) among patients who completed the trial, among patients who completed the trial, and the greater weight gain in the olanzaand the greater weight gain in the olanzapine-treated patients. Risperidone and pine-treated patients. Risperidone and olanzapine were among the five atypical olanzapine were among the five atypical 13 7 13 7 AUTHOR'S PROOF AUTHOR'S PROOF PANSS, Positive and Negative Syndrome Scale PANSS, Positive and Negative Syndrome Scale 1. Baseline PANSS scores were not available for 1 patient.The number of patients changes from the short-term to the 1. Baseline PANSS scores were not available for 1 patient.The number of patients changes from the short-term to the long-term outcome because some patients who received 75 mg of risperidone after week 13 did not receive 75 mg long-term outcome because some patients who received 75 mg of risperidone after week 13 did not receive 75 mg before week 13. before week 13. , 2005) . Time to treatment discontinuation (the primary outcome measure) was tion (the primary outcome measure) was significantly longer in patients receiving significantly longer in patients receiving olanzapine than risperidone (9.2 olanzapine than risperidone (9.2 v.
v. 4.8 4.8 Kaplan-Meier estimated median months, Kaplan-Meier estimated median months, P P5 50.01). However, similar improvements 0.01). However, similar improvements in PANSS total scores were seen in patients in PANSS total scores were seen in patients treated with risperidone and olanzapine at treated with risperidone and olanzapine at month 18, both in the total group month 18, both in the total group (Lieberman (Lieberman et al et al, 2005) and in patients , 2005) and in patients whose treatment had been switched to one whose treatment had been switched to one of these two antipsychotics after discontiof these two antipsychotics after discontinuing their previous treatments (Stroup nuing their previous treatments (Stroup et al et al, 2006) . There was some suggestion , 2006). There was some suggestion that olanzapine was not as well tolerated that olanzapine was not as well tolerated as risperidone: substantial differences as risperidone: substantial differences were noted in the proportions of patients were noted in the proportions of patients who discontinued treatment because of inwho discontinued treatment because of intolerability (10% of the risperidone patolerability (10% of the risperidone patients tients v.
v. 19% of the olanzapine patients; 19% of the olanzapine patients; P P5 50.05) and 2% of the risperidone 0.05) and 2% of the risperidone group group v.
v. 9% of the olanzapine group dis-9% of the olanzapine group discontinued because of weight gain or metacontinued because of weight gain or metabolic effects ( bolic effects (P P5 50.001, comparing all five 0.001, comparing all five treatment groups) (Lieberman treatment groups) (Lieberman et al et al, , 2005) . : similar proportions of patients in the risperidone and olanzapine groups the risperidone and olanzapine groups responded to treatment during the 12 responded to treatment during the 12 months (74 and 81%) or had relapsed (9 months (74 and 81%) or had relapsed (9 and 8%) (response and relapse were and 8%) (response and relapse were defined according to patient scores on the defined according to patient scores on the Clinical Global Impression-Schizophrenia Clinical Global Impression-Schizophrenia scale). scale).
In their meta-analysis of studies of In their meta-analysis of studies of atypical antipsychotics, Davis atypical antipsychotics, Davis et al et al (2003) (2003) reported that the effect sizes of risperidone reported that the effect sizes of risperidone and olanzapine (compared with convenand olanzapine (compared with conventional antipsychotics) were similar (0.25 tional antipsychotics) were similar (0.25 and 0.21 respectively) and highly signifiand 0.21 respectively) and highly significant ( cant (P P5 50.001). This analysis included 0.001). This analysis included data from 22 risperidone trials and 14 data from 22 risperidone trials and 14 olanzapine trials. olanzapine trials.
The primary efficacy result of our trial The primary efficacy result of our trial was that in the short term (weeks 1-13) was that in the short term (weeks 1-13) long-acting injectable risperidone was as long-acting injectable risperidone was as effective as oral olanzapine in the treateffective as oral olanzapine in the treatment of patients with schizophrenia or ment of patients with schizophrenia or schizoaffective disorder, an expected outschizoaffective disorder, an expected outcome given the previous findings of come given the previous findings of short-term studies of the oral formulations short-term studies of the oral formulations of the two agents. of the two agents.
Efficacy of the two treatments Efficacy of the two treatments
Significant reductions in PANSS total and Significant reductions in PANSS total and factor scores were seen in the analyses of factor scores were seen in the analyses of the short-term and long-term data in both the short-term and long-term data in both treatment groups. Patients receiving longtreatment groups. Patients receiving longacting risperidone demonstrated significant acting risperidone demonstrated significant benefits over treatment with olanzapine on benefits over treatment with olanzapine on two outcomes: clinical improvement (at two outcomes: clinical improvement (at least 20% reduction in PANSS total score) least 20% reduction in PANSS total score) at month 12 and at end-point, and imat month 12 and at end-point, and improvement on a PANSS factor at month provement on a PANSS factor at month 12 (disorganised thoughts). According to 12 (disorganised thoughts). According to the patients' ratings in both treatment the patients' ratings in both treatment groups, quality of life was improved from groups, quality of life was improved from baseline to end-point. baseline to end-point.
Long-term outcomes Long-term outcomes Figure 2 shows that the improvements with Figure 2 shows that the improvements with long-acting risperidone and olanzapine in long-acting risperidone and olanzapine in PANSS total scores and scores on three of PANSS total scores and scores on three of the five factors start to diverge at months the five factors start to diverge at months 9-12, suggesting more positive long-term 9-12, suggesting more positive long-term responses to long-acting risperidone than responses to long-acting risperidone than to olanzapine. A similar trend was evident to olanzapine. A similar trend was evident in the data on clinical improvement (at least in the data on clinical improvement (at least 20% reduction in PANSS total score). 20% reduction in PANSS total score). These results seem to be in line with those of These results seem to be in line with those of a previous study (Hogarty a previous study (Hogarty et al et al, 1979) , which , 1979), which reported comparable relapse rates with depot reported comparable relapse rates with depot and oral antipsychotics (fluphenazine decanoand oral antipsychotics (fluphenazine decanoate and fluphenazine hydrochloride) during ate and fluphenazine hydrochloride) during the first year of treatment (39 and 35% rethe first year of treatment (39 and 35% respectively), but substantially lower rates with spectively), but substantially lower rates with the depot medication the depot medication than with the oral than with the oral formulation during formulation during the second treatment the second treatment year (8 and 42% respectively). year (8 and 42% respectively).
The high medication adherence rates in The high medication adherence rates in this 1-year controlled study are notethis 1-year controlled study are noteworthy. The mean time off drug was 0.7 worthy. The mean time off drug was 0.7 days (s.d. days (s.d.¼3.7) in the oral olanzapine 3.7) in the oral olanzapine group, a substantially higher rate than regroup, a substantially higher rate than reported in 1-year and 2-year studies of ported in 1-year and 2-year studies of adherence rates in patients with schizoadherence rates in patients with schizophrenia receiving oral antipsychotics phrenia receiving oral antipsychotics (Gilmer (Gilmer et al et al, 2004; Weiden , 2004; Weiden et al, et al, 2004) . 2004). Thus, application of our findings to the Thus, application of our findings to the real-world effectiveness of the two medicareal-world effectiveness of the two medications will need to take into account the tions will need to take into account the impact of medication adherence rates on impact of medication adherence rates on treatment outcome. treatment outcome.
Tolerability Tolerability
A high proportion of the patients com-A high proportion of the patients completed the 1-year trial (65% of the longpleted the 1-year trial (65% of the longacting risperidone group and 62% of the acting risperidone group and 62% of the olanzapine group). Both treatments were olanzapine group). Both treatments were safe and well tolerated. Few patients (7 in safe and well tolerated. Few patients (7 in the risperidone group and 11 in the the risperidone group and 11 in the olanzapine group) withdrew from treatolanzapine group) withdrew from treatment be ment because of an adverse event. The cause of an adverse event. The incidence of extrapyramidal adverse events incidence of extrapyramidal adverse events was higher in the long-acting risperidone was higher in the long-acting risperidone group than in the olanzapine group at basegroup than in the olanzapine group at baseline, but by months 9-12 the rates were comline, but by months 9-12 the rates were comparable in the two groups (this does not parable in the two groups (this does not appear to be a result of differential withappear to be a result of differential withdrawal rates). New-onset tardive dyskinesia drawal rates). New-onset tardive dyskinesia (reported in two patients in each treatment (reported in two patients in each treatment group) was a rare event. Increases in body group) was a rare event. Increases in body weight and weight and BMI were significantly lower BMI were significantly lower in the longin the long-acting risperidone group than acting risperidone group than in the olanzapine group. in the olanzapine group.
Implications Implications
In patients with schizophrenia or schizoIn patients with schizophrenia or schizoaffective disorder, long-acting risperidone affective disorder, long-acting risperidone and olanzapine tablets were efficacious and olanzapine tablets were efficacious and well tolerated over the 12-month duraand well tolerated over the 12-month duration of this study. The efficacy results sugtion of this study. The efficacy results suggest that in the long term patients might gest that in the long term patients might benefit more from treatment with long-actbenefit more from treatment with long-acting risperidone than with oral olanzapine, ing risperidone than with oral olanzapine, but longer-term comparative data will help but longer-term comparative data will help to confirm these observations. to confirm these observations. 
